Michael Schilsky, MD

• Pramod Mistry
• Uyen To

Copper; Liver Transplantation; Liver Failure, Acute

• S1564 Lessons in Monitoring Chelation Therapy in “Stable” Wilson Disease Patients Screened for a Randomized TrialMedici V, Peralta R, Kamlin C, Heifets M, Schilsky M. S1564 Lessons in Monitoring Chelation Therapy in “Stable” Wilson Disease Patients Screened for a Randomized Trial. The American Journal Of Gastroenterology 2023, 118: s1180-s1181. DOI: 10.14309/01.ajg.0000955896.28554.ec.
• P20 Patterns of ALT, AST and 24-hour urine copper in adult patients with treated Wilson disease: results from an international multi-site registry at enrolment and over the course of 3 yearsCamarata M, To U, Coskun A, Maciejewski K, Embel V, Ayhan E, Gonzalez-Peralta R, Ala A, Schilsky M. P20 Patterns of ALT, AST and 24-hour urine copper in adult patients with treated Wilson disease: results from an international multi-site registry at enrolment and over the course of 3 years. 2023, a25.1-a25. DOI: 10.1136/gutjnl-2023-basl.36.
• P21 Monitoring maintenance therapy with D-Penicillamine for Wilson’s Disease: lessons from screening for a randomized trialAla A, Yin J, Moore J, Medici V, González-Peralta R, Kamlin C, Heifetz M, Ott P, Schilsky M. P21 Monitoring maintenance therapy with D-Penicillamine for Wilson’s Disease: lessons from screening for a randomized trial. 2023, a25.2-a26. DOI: 10.1136/gutjnl-2023-basl.37.
• Major Depressive Disorder in an International Multisite Wilson Disease RegistryCamarata M, Ala A, Coskun A, Deng Y, Embel V, Gonzalez-Peralta R, Maciejewski K, Patel A, Rubman S, To U, Tomlin R, Schilsky M, Zimbrean P. Major Depressive Disorder in an International Multisite Wilson Disease Registry. Journal Of The Academy Of Consultation-Liaison Psychiatry 2022, 64: 106-117. PMID: 36521682, DOI: 10.1016/j.jaclp.2022.12.001.
• O01 Efficacy and safety of ALXN1840 versus standard of care in Wilson disease: primary results from an ongoing phase 3, randomized, controlled, rater-blinded trialWeiss K, Schilsky M, Czlonkowska A, Askari F, Ala A, Ferenci P, Ott P, Abdurakhmanov D, Szalay F, Socha P, Shimizu N, Bronstein J, Bega D, Hahn S, Swenson E, Chen Y, Poujois A. O01 Efficacy and safety of ALXN1840 versus standard of care in Wilson disease: primary results from an ongoing phase 3, randomized, controlled, rater-blinded trial. 2022, a1-a1. DOI: 10.1136/gutjnl-2022-basl.1.
• FRI297 Defining the boundaries for “stability” in Wilson disease patients on maintenance chelation therapy: lessons from the CHELATE trialKamlin C, Schilsky M, Ott P, Weiss K, Zuin M, Poujois A, Ala A, D’Hollander K. FRI297 Defining the boundaries for “stability” in Wilson disease patients on maintenance chelation therapy: lessons from the CHELATE trial. Journal Of Hepatology 2022, 77: s539. DOI: 10.1016/s0168-8278(22)01402-7.
• GS001 Efficacy and safety of ALXN1840 versus standard of care in Wilson disease: primary results from an ongoing phase 3, randomized, controlled, rater-blinded trialWeiss K, Schilsky M, Czlonkowska A, Askari F, Ala A, Ferenci P, Ott P, Abdurakhmanov D, Szalay F, Socha P, Shimizu N, Bronstein J, Bega D, Hahn S, Swenson E, Chen Y, Poujois A. GS001 Efficacy and safety of ALXN1840 versus standard of care in Wilson disease: primary results from an ongoing phase 3, randomized, controlled, rater-blinded trial. Journal Of Hepatology 2022, 77: s1. DOI: 10.1016/s0168-8278(22)00428-7.
• OS077 Clinical utility of non-ceruloplasmin copper determined by copper speciation for monitoring Wilson disease therapy: comparative data analysis with 24-hour urinary copper excretion from the CHELATE trialSchilsky M, Poujois A, Zuin M, Ott P, Weiss K, Cassiman D, Ala A, Czlonkowska A, Dubois N, Amin N, Kamlin C. OS077 Clinical utility of non-ceruloplasmin copper determined by copper speciation for monitoring Wilson disease therapy: comparative data analysis with 24-hour urinary copper excretion from the CHELATE trial. Journal Of Hepatology 2022, 77: s61-s62. DOI: 10.1016/s0168-8278(22)00524-4.
• Résultats à un an de l’étude chelate : comparaison de la trientine tétrahydrochloride à la D-Pénicillamine chez des patients stables atteints de la maladie de WilsonPoujois A, Giovanni Z, Anna C, Obadia M, Henry A, Weiss K, Schilsky M. Résultats à un an de l’étude chelate : comparaison de la trientine tétrahydrochloride à la D-Pénicillamine chez des patients stables atteints de la maladie de Wilson. Revue Neurologique 2022, 178: s47. DOI: 10.1016/j.neurol.2022.02.226.
• Trientine tetrahydrochloride versus d-Penicillamine for the management of patients with Wilson Disease: results from the CHELATE trial a year after randomisationZuin M, Czlonkowska A, Cassiman D, Poujois A, Ott P, Dubois N, Weiss K, Monico S, Battezzati P, Carnevali G, Schilsky M, Investigators C. Trientine tetrahydrochloride versus d-Penicillamine for the management of patients with Wilson Disease: results from the CHELATE trial a year after randomisation. Digestive And Liver Disease 2022, 54: s2. DOI: 10.1016/j.dld.2022.01.007.
• Coagulopathy, Bleeding Events, and Outcome According to Rotational Thromboelastometry in Patients With Acute Liver Injury/FailureStravitz RT, Fontana RJ, Meinzer C, Durkalski‐Mauldin V, Hanje AJ, Olson J, Koch D, Hamid B, Schilsky M, McGuire B, Ganger D, Liou I, Karvellas CJ, Rule JA, Lisman T, Clasen K, Reuben A, Cripps M, Lee WM, Group A. Coagulopathy, Bleeding Events, and Outcome According to Rotational Thromboelastometry in Patients With Acute Liver Injury/Failure. Hepatology 2021, 74: 937-949. PMID: 33636020, PMCID: PMC10668528, DOI: 10.1002/hep.31767.
• Recent advances in Wilson diseaseMoini M, To U, Schilsky M. Recent advances in Wilson disease. Translational Gastroenterology And Hepatology 2021, 6: 21-21. DOI: 10.21037/tgh-2019-rld-10.
• P12 Effect of liver disease, neurological disease and mental health issues on quality of life in patients with wilson diseaseCamarata M, Ala A, Maciejewski K, To U, Zimbrean P, Rubman S, Coskun A, Patel A, Wadhwa A, Apdik T, Tomlin R, Deng Y, Gonzalez-Peralta R, Schilsky M. P12 Effect of liver disease, neurological disease and mental health issues on quality of life in patients with wilson disease. Gut 2020, 69: a13-a13. DOI: 10.1136/gutjnl-2020-basl.23.
• P13 Major depressive disorder in patients with wilson’s disease: relationship with liver disease, neurological disease and quality of lifeCamarata M, Ala A, Maciejewski K, To U, Zimbrean P, Rubman S, Patel A, Wadhwa A, Coskun A, Apdik T, Tomlin R, Deng Y, Schilsky M. P13 Major depressive disorder in patients with wilson’s disease: relationship with liver disease, neurological disease and quality of life. Gut 2020, 69: a13-a13. DOI: 10.1136/gutjnl-2020-basl.24.
• FRI303 Major depressive disorder in patients with Wilson’s disease: relationship with liver disease, neurological disease and quality of lifeCamarata M, Ala A, To U, Zimbrean P, Rubman S, Patel A, Wadhwa A, Maciejewski K, Song X, Deng Y, Tomlin R, Apdik T, Coskun A, Schilsky M. FRI303 Major depressive disorder in patients with Wilson’s disease: relationship with liver disease, neurological disease and quality of life. Journal Of Hepatology 2020, 73: s550-s551. DOI: 10.1016/s0168-8278(20)31573-7.
• 257 Bipolar disorder in patients with Wilson diseaseZimbrean P, Rubman S, Maciejewski K, Coskun, Nalamada K, Camarata M, Tomlin R, Patel A, To U, Ala A, Gonzalez-Peralta R, Deng Y, Schilsky M. 257 Bipolar disorder in patients with Wilson disease. Journal Of Psychosomatic Research 2020, 133: 110055. DOI: 10.1016/j.jpsychores.2020.110055.
• Inherited diseases of copper metabolism: Wilson’s disease and Menkes’ diseaseSchilsky M, Mistry P. Inherited diseases of copper metabolism: Wilson’s disease and Menkes’ disease. 2020, c12.7.2-c12.7.2.s26. DOI: 10.1093/med/9780198746690.003.0234.
• Major depressive disorder in patients with Wilson diseaseZimbrean P, Gold S, Nalamada K, Camarata M, Tomlin R, Patel A, Vives-Rodrigues A, Ekong U, Bramford N, Valentino P, To U, Deng Y, Song X, Ala A, Schilsky M. Major depressive disorder in patients with Wilson disease. Journal Of Psychosomatic Research 2019, 121: 148. DOI: 10.1016/j.jpsychores.2019.03.145.
• FRI-425-Maintenance therapy for Wilson disease with zinc: A comparison between zinc acetate and alternative zinc saltsCamarata M, Ala A, Schilsky M. FRI-425-Maintenance therapy for Wilson disease with zinc: A comparison between zinc acetate and alternative zinc salts. Journal Of Hepatology 2019, 70: e581. DOI: 10.1016/s0618-8278(19)31162-4.
• Wilson's DiseaseKelly C, Ala A, Schilsky M. Wilson's Disease. 2019, 554-573. DOI: 10.1002/9781119211419.ch37.
• Chapter 39 New Treatment Modalities in Wilson DiseaseSchilsky M. Chapter 39 New Treatment Modalities in Wilson Disease. 2019, 399-405. DOI: 10.1016/b978-0-12-810532-0.00039-2.
• Chapter 15 General Considerations and the Need for Liver TransplantationCamarata M, Weiss K, Schilsky M. Chapter 15 General Considerations and the Need for Liver Transplantation. 2019, 173-182. DOI: 10.1016/b978-0-12-811077-5.00015-3.
• Chapter 23 Special Treatment Considerations for Wilson DiseaseCamarata M, Weiss K, Schilsky M. Chapter 23 Special Treatment Considerations for Wilson Disease. 2019, 235-245. DOI: 10.1016/b978-0-12-811077-5.00023-2.
• The Epidemiology of Rare Hereditary Metabolic Liver DiseasesPericleous M, Kelly C, Ala A, Schilsky M. The Epidemiology of Rare Hereditary Metabolic Liver Diseases. 2018, 307-330. DOI: 10.1007/978-3-319-94355-8_17.
• Monitoring Treatment of Wilson DiseaseMiloh T, Schilsky M. Monitoring Treatment of Wilson Disease. 2018, 143-159. DOI: 10.1007/978-3-319-91527-2_8.
• Wilson Disease: Special CircumstancesCamarata M, Schilsky M. Wilson Disease: Special Circumstances. 2018, 175-181. DOI: 10.1007/978-3-319-91527-2_10.
• Liver Transplantation for Wilson DiseaseMiloh T, Schilsky M. Liver Transplantation for Wilson Disease. 2018, 183-202. DOI: 10.1007/978-3-319-91527-2_11.
• Treatment Options for Wilson DiseaseKelly C, Pericleous M, Schilsky M. Treatment Options for Wilson Disease. 2018, 45-61. DOI: 10.1007/978-3-319-91527-2_3.
• Treating Other Symptoms of Wilson Disease: The LiverCamarata M, Schilsky M. Treating Other Symptoms of Wilson Disease: The Liver. 2018, 87-106. DOI: 10.1007/978-3-319-91527-2_5.
• Diagnosis Confirmation and Screening of Wilson DiseasePericleous M, Kelly C, Schilsky M. Diagnosis Confirmation and Screening of Wilson Disease. 2018, 17-44. DOI: 10.1007/978-3-319-91527-2_2.
• Partnering for Care of Wilson DiseaseGraper M, Schilsky M. Partnering for Care of Wilson Disease. 2018, 203-212. DOI: 10.1007/978-3-319-91527-2_12.
• Introduction to Copper Metabolism and Wilson DiseaseTo U, Schilsky M. Introduction to Copper Metabolism and Wilson Disease. 2018, 1-16. DOI: 10.1007/978-3-319-91527-2_1.
• Posters Thursday, 12 April 2018Weiss K, Askari F, Ferenci P, Ala A, Czlonkowska A, Nicholl D, Bronstein J, Bega D, Schilsky M. Posters Thursday, 12 April 2018. Journal Of Hepatology 2018, 68: s105-s364. DOI: 10.1016/s0168-8278(18)30428-8.
• Chapter 19 Wilson Disease and Related DisordersSchilsky M. Chapter 19 Wilson Disease and Related Disorders. 2018, 253-268. DOI: 10.1016/b978-0-323-47874-8.00019-5.
• Update on Wilson disease: focus on WTX-101Camarata M, Ala A, Schilsky M. Update on Wilson disease: focus on WTX-101. Drugs Of The Future 2018, 43: 501. DOI: 10.1358/dof.2018.043.07.2819432.
• Wilson DiseaseSchilsky M, Ala A. Wilson Disease. 2017, 799-819. DOI: 10.1002/9781119251316.ch29.
• Association of Variants of Arginine Vasopressin and Arginine Vasopressin Receptor 1A With Severe Acetaminophen Liver InjuryRandesi M, Levran O, da Rosa J, Hankins J, Rule J, Kreek M, Lee W, Group A, Reuben A, Fontana R, Davern T, McGuire B, Stravitz R, Durkalski V, Liou I, Fix O, Schilsky M, Ganger D, Chung R, Koch D, Reddy K, Rossaro L. Association of Variants of Arginine Vasopressin and Arginine Vasopressin Receptor 1A With Severe Acetaminophen Liver Injury. Cellular And Molecular Gastroenterology And Hepatology 2017, 3: 500-505. PMID: 28462386, PMCID: PMC5404026, DOI: 10.1016/j.jcmgh.2017.01.008.
• GS-016 WTX101 in patients newly diagnosed with Wilson disease: final results of a global, prospective phase 2 trialWeiss K, Askari F, Ferenci P, Ala A, Czlonkowska A, Nicholl D, Bronstein J, Bega D, Schilsky M. GS-016 WTX101 in patients newly diagnosed with Wilson disease: final results of a global, prospective phase 2 trial. Journal Of Hepatology 2017, 66: s88. DOI: 10.1016/s0168-8278(17)30440-3.
• PS020 An Ongoing Phase 2, Multi-Centre, Open-Label, Study of WTX101 in Newly Diagnosed Wilson Disease Patients – Early ObservationsWeiss K, Ala A, Askari F, Bega D, Bronstein J, Czlonkowska A, Ferenci P, Nicholl D, Schilsky M. PS020 An Ongoing Phase 2, Multi-Centre, Open-Label, Study of WTX101 in Newly Diagnosed Wilson Disease Patients – Early Observations. Journal Of Hepatology 2016, 64: s145-s146. DOI: 10.1016/s0168-8278(16)00033-7.
• Tu1044 Sofosbuvir-Based Interferon-Free Regimens for Hepatitis C Infection in Patients With Compensated and Decompensated Cirrhosis: Interim Analysis of a Prospective Observational CohortDo A, Lim J, Liapakis A, Babas G, Caldwell C, Fortune B, Emre S, Kulkarni S, Lempit S, Mistry P, Mulligan D, Rodriguez-Davalos M, Schilsky M, Tichy E, Yoo P, Jakab S. Tu1044 Sofosbuvir-Based Interferon-Free Regimens for Hepatitis C Infection in Patients With Compensated and Decompensated Cirrhosis: Interim Analysis of a Prospective Observational Cohort. Gastroenterology 2015, 148: s-1094-s-1095. DOI: 10.1016/s0016-5085(15)33733-1.
• P1313 : WTX101–201 : Phase 2 study of bis-choline tetrathiomolybdate in newly diagnosed wilson disease patientsWeiss K, Askari F, Ferenci P, Czlonkowska A, Bronstein J, Schilsky M, Clark D, Hansson J. P1313 : WTX101–201 : Phase 2 study of bis-choline tetrathiomolybdate in newly diagnosed wilson disease patients. Journal Of Hepatology 2015, 62: s847. DOI: 10.1016/s0168-8278(15)31492-6.
• Su1011 Should Liver Transplantation Be Reconsidered in Patients With Intrahepatic Cholangiocarcinoma? A Systematic Review and Meta-Regression Analysis of Epidemiologic EvidenceNjei B, Schilsky M, Ditah I, Taddei T. Su1011 Should Liver Transplantation Be Reconsidered in Patients With Intrahepatic Cholangiocarcinoma? A Systematic Review and Meta-Regression Analysis of Epidemiologic Evidence. Gastroenterology 2015, 148: s-1036. DOI: 10.1016/s0016-5085(15)33541-1.
• Prospective Pilot Study of a Single Daily Dosage of Trientine for the Treatment of Wilson DiseaseAla A, Aliu E, Schilsky ML. Prospective Pilot Study of a Single Daily Dosage of Trientine for the Treatment of Wilson Disease. Digestive Diseases And Sciences 2015, 60: 1433-1439. PMID: 25605552, PMCID: PMC4427615, DOI: 10.1007/s10620-014-3495-6.
• Therapeutic hypothermia in acute liver failure: A multicenter retrospective cohort analysisKarvellas CJ, Stravitz R, Battenhouse H, Lee WM, Schilsky ML, Group F. Therapeutic hypothermia in acute liver failure: A multicenter retrospective cohort analysis. Liver Transplantation 2015, 21: 4-12. PMID: 25308108, PMCID: PMC4939841, DOI: 10.1002/lt.24021.
• Radiology in TransplantKim A, Schilsky M. Radiology in Transplant. Current Transplantation Reports 2014, 1: 238-245. DOI: 10.1007/s40472-014-0034-5.
• Right Homonymous Hemianopsia and Seizures in a Liver Transplant RecipientThiessen C, Patrón‐Lozano R, Schilsky M, Rodríguez‐Dávalos M. Right Homonymous Hemianopsia and Seizures in a Liver Transplant Recipient. American Journal Of Transplantation 2014, 14: 2427-2429. PMID: 25231067, DOI: 10.1111/ajt.12870.
• In Memoriam: H. Ascher Sellner, M.D.Kaler S, Schilsky M. In Memoriam: H. Ascher Sellner, M.D. Annals Of The New York Academy Of Sciences 2014, 1314: iv-iv. DOI: 10.1111/nyas.12449.
• P319 HYPOTHERMIA IN ACUTE LIVER FAILURE: A MULTI-CENTRE RETROSPECTIVE COHORT ANALYSIS (IT'S ALRIGHT TO BE COOL)Karvellas C, Stravitz R, Battenhouse H, Durkalski V, Lee W, Schilsky M. P319 HYPOTHERMIA IN ACUTE LIVER FAILURE: A MULTI-CENTRE RETROSPECTIVE COHORT ANALYSIS (IT'S ALRIGHT TO BE COOL). Journal Of Hepatology 2014, 60: s173. DOI: 10.1016/s0168-8278(14)60481-5.
• A multicenter retrospective cohort analysis of therapeutic hypothermia in acute liver failureKarvellas C, Stravitz R, Battenhouse H, Durkalski V, Lee W, Schilsky M. A multicenter retrospective cohort analysis of therapeutic hypothermia in acute liver failure. Critical Care 2014, 18: p200. PMCID: PMC4068622, DOI: 10.1186/cc13390.
• 730McGinniss J, Marshall P, Schilsky M, Honiden S. 730. Critical Care Medicine 2013, 41: a180-a181. DOI: 10.1097/01.ccm.0000439968.28678.d4.
• Acute Liver and Multi-organ Failure Secondary to Intentional Iron OverdoseRuss K, Khan A, James L, Schilsky M, Fix O, Lee W, McGuire B. Acute Liver and Multi-organ Failure Secondary to Intentional Iron Overdose. The American Journal Of Gastroenterology 2013, 108: s324. DOI: 10.14309/00000434-201310001-01086.
• Human Monoclonal Antibody MBL-HCV1 Delays HCV Viral Rebound Following Liver Transplantation: A Randomized Controlled StudyChung R, Gordon F, Curry M, Schiano T, Emre S, Corey K, Markmann J, Hertl M, Pomposelli J, Pomfret E, Florman S, Schilsky M, Broering T, Finberg R, Szabo G, Zamore P, Khettry U, Babcock G, Ambrosino D, Leav B, Leney M, Smith H, Molrine D. Human Monoclonal Antibody MBL-HCV1 Delays HCV Viral Rebound Following Liver Transplantation: A Randomized Controlled Study. American Journal Of Transplantation 2013, 13: 1047-1054. PMID: 23356386, PMCID: PMC3618536, DOI: 10.1111/ajt.12083.
• Ferenci P, Czlonkowska A, Stremmel W, Houwen R, Rosenberg W, Schilsky M, Jansen P, Moradpour D, Gitlin J. EASL Clinical Practice Guidelines: Wilson's disease.European Association for Study of Liver. J Hepatol. 56:671-685
• Wilson DiseaseSchilsky M, Tavill A. Wilson Disease. 2011, 803-824. DOI: 10.1002/9781119950509.ch29.
• Wilson Disease: Pathogenesis and Clinical Considerations in Diagnosis and TreatmentRosencrantz1 2, Schilsky2 3. Wilson Disease: Pathogenesis and Clinical Considerations in Diagnosis and Treatment. Seminars In Liver Disease 2011, 31: 245-259. PMID: 21901655, DOI: 10.1055/s-0031-1286056.
• Genetic Modifiers of Liver Injury in Hereditary Liver DiseaseAla A, Schilsky M. Genetic Modifiers of Liver Injury in Hereditary Liver Disease. Seminars In Liver Disease 2011, 31: 208-214. PMID: 21538285, DOI: 10.1055/s-0031-1276648.
• Wilson’s DiseaseSchilsky M, Mitchell K. Wilson’s Disease. 2010, 5: 655-663. DOI: 10.1007/978-1-4419-7107-4_43.
• Inherited diseases of copper metabolism: Wilson’s disease and Menkes’ diseaseSchilsky M, Mistry P. Inherited diseases of copper metabolism: Wilson’s disease and Menkes’ disease. 2010, 1688-1693. DOI: 10.1093/med/9780199204854.003.120702.
• Copper Metabolism and the LiverSchilsky M, Thiele D. Copper Metabolism and the Liver. 2009, 221-233. DOI: 10.1002/9780470747919.ch15.
• T1002 Clinical Epidemiology of Wilson Disease in Patients with Concurrent Liver DiseaseWong R, Gish R, Schilsky M, Frenette C. T1002 Clinical Epidemiology of Wilson Disease in Patients with Concurrent Liver Disease. Gastroenterology 2009, 136: a-844. DOI: 10.1016/s0016-5085(09)63889-0.
• M1731 Wilson Disease and Outcomes After Liver TransplantationArnon R, Annunziato R, Schilsky M, Miloh T, Suchy F, Iyer K, Kerkar N. M1731 Wilson Disease and Outcomes After Liver Transplantation. Gastroenterology 2009, 136: a-420. DOI: 10.1016/s0016-5085(09)61931-4.
• Reply:Schilsky M, Lee W, Wiands F. Reply:. Hepatology 2009, 49: 1784-1784. DOI: 10.1002/hep.22954.
• ICU Management of Acute Liver FailureSchilsky ML, Honiden S, Arnott L, Emre S. ICU Management of Acute Liver Failure. Clinics In Chest Medicine 2009, 30: 71-87. PMID: 19186281, DOI: 10.1016/j.ccm.2008.10.001.
• Chapter 42 Wilson Disease and the KidneySchilsky M, Mistry P. Chapter 42 Wilson Disease and the Kidney. 2009, 709-713. DOI: 10.1016/b978-0-12-449851-8.00042-5.
• Screening for Wilson disease in acute liver failure: A comparison of currently available diagnostic testsKorman JD, Volenberg I, Balko J, Webster J, Schiodt FV, Squires RH, Fontana RJ, Lee WM, Schilsky ML, Groups P. Screening for Wilson disease in acute liver failure: A comparison of currently available diagnostic tests. Hepatology 2008, 48: 1167-1174. PMID: 18798336, PMCID: PMC4881751, DOI: 10.1002/hep.22446.
• Diagnosis and treatment of Wilson disease: An updateRoberts EA, Schilsky ML. Diagnosis and treatment of Wilson disease: An update. Hepatology 2008, 47: 2089-2111. PMID: 18506894, DOI: 10.1002/hep.22261.
• Tetrathiomolybdate versus Trientine in the Initial Treatment of Neurologic Wilson's DiseaseBrewer G, Askari F, Lorincz M, Carlson M, Schilsky M, Kluin K, Hedera P, Moretti P, Fink J, Tankanow R, Dick R, Sitterly J. Tetrathiomolybdate versus Trientine in the Initial Treatment of Neurologic Wilson's Disease. 2008, 153-166. DOI: 10.1017/cbo9780511666971.010.
• Tetrathiomolybdate versus Trientine in the Initial Treatment of Neurologic Wilson's DiseaseBrewer G, Askari F, Lorincz M, Carlson M, Schilsky M, Kluin K, Hedera P, Moretti P, Fink J, Tankanow R, Dick R, Sitterly J. Tetrathiomolybdate versus Trientine in the Initial Treatment of Neurologic Wilson's Disease. Progress In Neurotherapeutics And Neuropsychopharmacology 2007, 3 DOI: 10.1017/s1748232107000043.
• Chapter 38 The Transplant Operation: What the Hepatologist Should KnowSchilsky M, Kinkhabwala M, Emond J. Chapter 38 The Transplant Operation: What the Hepatologist Should Know. 2006, 605-620. DOI: 10.1016/b978-0-323-03675-7.50042-1.
• Survival After Liver Transplantation in Patients With Hepatic Iron Overload: The National Hemochromatosis Transplant RegistryKOWDLEY K, BRANDHAGEN D, GISH R, BASS N, WEINSTEIN J, SCHILSKY M, FONTANA R, MCCASHLAND T, COTLER S, BACON B, Keeffe E, Gordon F, Polissar N. Survival After Liver Transplantation in Patients With Hepatic Iron Overload: The National Hemochromatosis Transplant Registry. Gastroenterology 2005, 129: 494-503. DOI: 10.1016/j.gastro.2005.05.004.
• Wilson's DiseaseSchilsky M. Wilson's Disease. 2004, 643-647. DOI: 10.1016/b0-12-386860-2/00731-0.
• Corrections: A practice guideline on Wilson diseaseRoberts E, Schilsky M. Corrections: A practice guideline on Wilson disease. Hepatology 2003, 38: 536-536. DOI: 10.1002/hep.510380241.
• Elevation of serum ferritin and survival of patients with acute liver failureKorman J, Schiodt F, Balko J, Lee W, Schilsky M, Group A. Elevation of serum ferritin and survival of patients with acute liver failure. Gastroenterology 2003, 124: a756. DOI: 10.1016/s0016-5085(03)83818-0.
• Mechanism of sestamibi retention and clearance from myocardium and other organsJoseph B, Bhargava K, Kandimalla J, Malhi H, Schilsky M, Palestro C, Jain D, Gupta S. Mechanism of sestamibi retention and clearance from myocardium and other organs. Journal Of The American College Of Cardiology 2003, 41: 444. DOI: 10.1016/s0735-1097(03)81349-9.
• 640 HCV alternate reading frame proteins (ARFPS) may be virulence factors that help the virus survive adverse conditionsBranch A, Walewski J, Gutierrez J, Fernandez E, Im G, Dieterich D, Schiano T, Sigal S, Schilsky M, Schwartz M, Kyrk C, Muerhoff A, Leary T, Stewart J, Dawson G, Desai S. 640 HCV alternate reading frame proteins (ARFPS) may be virulence factors that help the virus survive adverse conditions. Hepatology 2003, 38: 468-469. DOI: 10.1016/s0270-9139(03)80682-1.
• 815 Molecular epidemiology of hepatitis B virus-related acute liver failure in the United States: a multicenter case control studyWai C, Fontana R, Schilsky M, McCashland T, Han S, Polson J, Hussain M, Lee W, Lok A. 815 Molecular epidemiology of hepatitis B virus-related acute liver failure in the United States: a multicenter case control study. Hepatology 2003, 38: 555. DOI: 10.1016/s0270-9139(03)80857-1.
• The irony of treating Wilson's diseaseSchilsky M. The irony of treating Wilson's disease. The American Journal Of Gastroenterology 2001, 96: ajg2001764. PMID: 11721750, DOI: 10.1111/j.1572-0241.2001.05254.x.
• ORTHOTOPIC LIVER TRANSPLANTATION FOR WILSON’S DISEASEEmre S, Atillasoy E, Ozdemir S, Schilsky M, Varma C, Thung S, Sternlieb I, Guy S, Sheiner P, Schwartz M, Miller C. ORTHOTOPIC LIVER TRANSPLANTATION FOR WILSON’S DISEASE. Transplantation 2001, 72: 1232-1236. PMID: 11602847, DOI: 10.1097/00007890-200110150-00008.
• Metabolic liver diseaseSchilsky M, Mistry P. Metabolic liver disease. Current Opinion In Gastroenterology 2001, 17: 221-231. PMID: 17031163, DOI: 10.1097/00001574-200105000-00005.
• Correction of Liver Disease Following Transplantation of Normal Rat Hepatocytes into Long–Evans Cinnamon Rats Modeling Wilson's DiseaseIrani A, Malhi H, Slehria S, Gorla G, Volenberg I, Schilsky M, Gupta S. Correction of Liver Disease Following Transplantation of Normal Rat Hepatocytes into Long–Evans Cinnamon Rats Modeling Wilson's Disease. Molecular Therapy 2001, 3: 302-309. PMID: 11273771, DOI: 10.1006/mthe.2001.0271.
• Treatment of Wilson’s disease: What are the relative roles of penicillamine, trientine, and zinc supplementation?Schilsky M. Treatment of Wilson’s disease: What are the relative roles of penicillamine, trientine, and zinc supplementation? Current Gastroenterology Reports 2001, 3: 54-59. PMID: 11177695, DOI: 10.1007/s11894-001-0041-4.
• Inherited metabolic diseaseSchilsky M, Mistry P. Inherited metabolic disease. Current Opinion In Gastroenterology 2000, 16: 219-230. PMID: 17023879, DOI: 10.1097/00001574-200005000-00004.
• Biliary copper excretion capacity in intact animals: Correlation between ATP7B function, hepatic mass, and biliary copper excretionSchilsky M, Irani A, Gorla G, Volenberg I, Gupta S. Biliary copper excretion capacity in intact animals: Correlation between ATP7B function, hepatic mass, and biliary copper excretion. Journal Of Biochemical And Molecular Toxicology 2000, 14: 210-214. PMID: 10789499, DOI: 10.1002/(sici)1099-0461(2000)14:4<210::aid-jbt5>3.0.co;2-g.
• Inherited metabolic diseaseSchilsky M. Inherited metabolic disease. Current Opinion In Gastroenterology 1999, 15: 200-207. PMID: 17023946, DOI: 10.1097/00001574-199905000-00004.
• Wilson’s diseaseTavill A, Schilsky M. Wilson’s disease. Current Treatment Options In Gastroenterology 1999, 2: 68-71. PMID: 11096575, DOI: 10.1007/s11938-999-0021-6.
• Fractionation of Rat Hepatocyte Subpopulations with Varying Metabolic Potential, Proliferative Capacity, and Retroviral Gene Transfer EfficiencyRajvanshi P, Liu D, Ott M, Gagandeep S, Schilsky M, Gupta S. Fractionation of Rat Hepatocyte Subpopulations with Varying Metabolic Potential, Proliferative Capacity, and Retroviral Gene Transfer Efficiency. Experimental Cell Research 1998, 244: 405-419. PMID: 9806791, DOI: 10.1006/excr.1998.4223.
• Copper resistant human hepatoblastoma mutant cell lines without metallothionein induction overexpress ATP7BSchilsky M, Stockert R, Kesner A, Gorla G, Gagliardi G, Terada K, Miura N, Czaja M. Copper resistant human hepatoblastoma mutant cell lines without metallothionein induction overexpress ATP7B. Hepatology 1998, 28: 1347-1356. PMID: 9794921, DOI: 10.1002/hep.510280525.
• ATP7B (WND) proteinTerada K, Schilsky M, Miura N, Sugiyama T. ATP7B (WND) protein. The International Journal Of Biochemistry & Cell Biology 1998, 30: 1063-1067. PMID: 9785470, DOI: 10.1016/s1357-2725(98)00073-9.
• Inherited metabolic diseaseSchilsky M. Inherited metabolic disease. Current Opinion In Gastroenterology 1998, 14: 200-207. DOI: 10.1097/00001574-199805000-00004.
• Identification of B10, an alkaline phosphodiesterase of the apical plasma membrane of hepatocytes and biliary cells, in rat serum: Increased levels following bile duct ligation and during the development of cholangiocarcinomaMeerson N, Delautier D, Durand‐Schneider A, Moreau A, Schilsky M, Sternlieb I, Feldmann G, Maurice M. Identification of B10, an alkaline phosphodiesterase of the apical plasma membrane of hepatocytes and biliary cells, in rat serum: Increased levels following bile duct ligation and during the development of cholangiocarcinoma. Hepatology 1998, 27: 563-568. PMID: 9462658, DOI: 10.1002/hep.510270234.
• Wilson’s DiseaseSchilsky M, Sternlieb I. Wilson’s Disease. 1998, 285-292. DOI: 10.1007/978-1-4612-1808-1_21.
• Genetic HemochromatosisSchilsky M, Sternlieb I. Genetic Hemochromatosis. 1998, 241-247. DOI: 10.1007/978-1-4612-1808-1_18.
• Inherited metabolic diseaseSchilsky M. Inherited metabolic disease. Current Opinion In Gastroenterology 1997, 13: 194-198. DOI: 10.1097/00001574-199705000-00004.
• An array of mitochondrial alterations in the hepatocytes of long‐evans cinnamon ratsSternlieb I, Quintana N, Volenberg I, Schilsky M. An array of mitochondrial alterations in the hepatocytes of long‐evans cinnamon rats. Hepatology 1995, 22: 1782-1787. PMID: 7489989, DOI: 10.1002/hep.1840220626.
• An array of mitochondrial alterations in the hepatocytes of Long-Evans Cinnamon ratsSternlieb I, Quintana N, Volenberg I, Schilsky M. An array of mitochondrial alterations in the hepatocytes of Long-Evans Cinnamon rats. Hepatology 1995, 22: 1782-1787. DOI: 10.1016/0270-9139(95)90206-6.
• In vitro modeling of liver membrane copper transportSchilsky M. In vitro modeling of liver membrane copper transport. Hepatology 1995, 22: 1340-1342. PMID: 7557893, DOI: 10.1002/hep.1840220449.
• In Vitro modeling of liver membrane copper transports Dijkstra M, Veld GI, van den Berg GJ, Muller M, Kuipers F, Vonk RJ. J. Clin Invest 1995; 95: 412–416Schilsky M. In Vitro modeling of liver membrane copper transports Dijkstra M, Veld GI, van den Berg GJ, Muller M, Kuipers F, Vonk RJ. J. Clin Invest 1995; 95: 412–416. Hepatology 1995, 22: 1340-1342. DOI: 10.1016/0270-9139(95)90651-7.
• Secretion, Surface Localization, Turnover, and Steady State Expression of Protein Disulfide Isomerase in Rat Hepatocytes (∗)Terada K, Manchikalapudi P, Noiva R, Jauregui H, Stockert R, Schilsky M. Secretion, Surface Localization, Turnover, and Steady State Expression of Protein Disulfide Isomerase in Rat Hepatocytes (∗). Journal Of Biological Chemistry 1995, 270: 20410-20416. PMID: 7657616, DOI: 10.1074/jbc.270.35.20410.
• Conditional immortalization of gunn rat hepatocytes: An ex vivo model for evaluating methods for bilirubin‐UDP‐glucuronosyltransferase gene transferFox I, Chowdhury N, Gupta S, Kondapalli R, Schilsky M, Stockert R, Chowdhury J. Conditional immortalization of gunn rat hepatocytes: An ex vivo model for evaluating methods for bilirubin‐UDP‐glucuronosyltransferase gene transfer. Hepatology 1995, 21: 837-846. PMID: 7875682, DOI: 10.1002/hep.1840210334.
• Conditional immortalization of gunn rat hepatocytes: An ex vivo model for evaluating methods for bilirubin-UDP-glucuronosyltransferase gene transferFox I, Chowdhury N, Gupta S, Kondapalli R, Schilsky M, Stockert R, Chowdhury J. Conditional immortalization of gunn rat hepatocytes: An ex vivo model for evaluating methods for bilirubin-UDP-glucuronosyltransferase gene transfer. Hepatology 1995, 21: 837-846. DOI: 10.1016/0270-9139(95)90539-1.
• Identification of the Wilson's disease gene: Clues for disease pathogenesis and the potential for molecular diagnosisSchilsky M. Identification of the Wilson's disease gene: Clues for disease pathogenesis and the potential for molecular diagnosis. Hepatology 1994, 20: 529-533. PMID: 8045514, DOI: 10.1002/hep.1840200235.
• Liver transplantation for Wilson's disease: Indications and outcomeSchilsky M, Scheinberg I, Sternlieb I. Liver transplantation for Wilson's disease: Indications and outcome. Hepatology 1994, 19: 583-587. PMID: 8119682, DOI: 10.1002/hep.1840190307.
• Biochemistry and molecular biology of the liverSchilsky M, Shafritz D. Biochemistry and molecular biology of the liver. Current Opinion In Gastroenterology 1992, 8: 418-425. DOI: 10.1097/00001574-199206000-00009.
• Prognosis of Wilsonian chronic active hepatitisSchilsky M, Scheinberg I, Sternlieb I. Prognosis of Wilsonian chronic active hepatitis. Gastroenterology 1991, 100: 762-767. PMID: 1993498, DOI: 10.1016/0016-5085(91)80023-3.
• PENICILLAMINE MAY DETOXIFY COPPER IN WILSON'S DISEASEScheinberg I, Sternlieb I, Schilsky M, Stockert R. PENICILLAMINE MAY DETOXIFY COPPER IN WILSON'S DISEASE. The Lancet 1987, 330: 95. PMID: 2885586, DOI: 10.1016/s0140-6736(87)92753-x.